DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that the U.S. Food and Drug Administration (FDA) has approved a new reconstitution system for ADVATE ...
Baxter announced that the FDA has approved BAXJECT III, a new reconstitution system for Advate (Antihemophilic Factor VIII [recombinant]). The new reconstitution system was developed to reduce the ...
Adynovate, which was approved by the regulatory agency in 2015 for use in hemophilia A patients 12 and older, is an extended circulating half-life recombinant Factor VIII treatment built on the ...
Deerfield, Ill., July 25, 2003 -- Baxter Healthcare Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved ADVATE (Antihemophilic Factor (Recombinant), ...
SEVILLE, Spain, World Federation of Haemophilia Congress, May 21, 2002 -- Baxter BioScience today announced the launch of the BAXJECT needleless transfer device (BAXJECT), a safer, faster and easier ...
Shire announced that the Food and Drug Administration (FDA) has approved the Baxject III reconstitution system for Adynovate (antihemophilic factor [recombinant], PEGylated). The Baxject III system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results